Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.
about
Signaling pathways in the development of infantile hemangiomaRegulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasisMonitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumabLow concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice.Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells.A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine SignalingPathogenesis of infantile haemangioma.The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia.Glioma stem cells enhance endothelial cell migration and proliferation via the Hedgehog pathwayEducational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I).Educational paper: therapy of infantile haemangioma--history and current state (part II).The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.Knockdown of VEGFR2 inhibits proliferation and induces apoptosis in hemangioma-derived endothelial cells.Natural products-prompted chemical biology: phenotypic screening and a new platform for target identification.Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia.Infantile Periocular Hemangioma.Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo.A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report.Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres.Advances in the Medical Management of Vascular Anomalies.Support for the hypoxia theory in the pathogenesis of infantile haemangioma.Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.Propranolol for the treatment of vascular sarcomas
P2860
Q26996608-06DD3C5F-3119-49E3-9D05-7D3C987A9AD6Q28504689-E0569362-96A6-41DE-AEAD-1C076671DE8DQ33740232-FE91D395-0E2C-494A-9F04-CB8CB38396C5Q34498996-61629431-0477-4F14-B7B2-E46CD38C98ECQ34501488-BE19DD22-489A-4E7E-ABE7-0617FBBF7E93Q34734440-0E2A7681-E678-4A49-B431-EC73630508A9Q36279494-070C18E1-733C-4C8F-8ED0-00F4EE569C87Q36788733-37E88DD2-7C22-412B-998D-620839067350Q37001304-C46B6123-A20C-4048-AF3A-FF102580E692Q37102306-036B593B-3900-4205-9A2A-E26EE723952AQ37269596-D9EC55D8-A9D6-4F6F-86C9-ECD27444AC7FQ38243260-C868DD00-56AF-42A5-9B2E-9AFB5CA7752DQ38245341-D95CFC58-BD3A-46F6-9961-C40C96F80E0BQ38246692-10A5E06C-83E8-4E9E-8101-46BE62765654Q38667341-D44CAB25-B9AB-4ED3-8289-0789919861C3Q38736299-0415BCD1-43CC-4A65-AA14-EC1DFD4B47B3Q39111280-66897AC3-5705-4019-A870-0F747338CE84Q39195618-C202397C-1D1C-44B1-9FDD-9CF3BFD60AE4Q39327604-22145A50-A2FB-4966-84A8-234BDE15020CQ47166468-1FC8498D-B42A-490D-8F78-D01E3C687CFEQ47249592-9A273756-EC1D-4705-9E7B-5CBF385259C0Q49384897-54E33F53-A14C-4D49-94DD-DE5E43969FCFQ49711115-2893F94F-2D78-491E-8581-96A7365F0053Q51674697-04B8E7D7-3641-43A1-A6D5-5D920ECD06E2Q54941077-EF1E326F-28FD-46B8-A8B3-DC16B7C4C6BBQ55435436-F81E9BC6-419F-4EE0-9ABF-22DDDCB7FB5EQ58761654-06228449-523D-43A4-A116-3D2F01811B1A
P2860
Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@ast
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@en
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@nl
type
label
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@ast
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@en
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@nl
prefLabel
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@ast
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@en
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@nl
P2860
P1433
P1476
Rapamycin inhibits proliferati ...... -dependent expression of VEGF.
@en
P2093
Bjorn R Olsen
Damian Medici
P2860
P304
P356
10.1371/JOURNAL.PONE.0042913
P407
P577
2012-08-10T00:00:00Z